SR0735 LRB103 35953 MST 66040 r
1		SENATE RESOLUTION
2		WHEREAS, Many people living with serious mental illnesses,
3		including bipolar disorder, major depressive disorder,
4		schizophrenia, and schizoaffective disorder or
5		gastrointestinal disorders such as gastroparesis, upset
6		stomach, nausea, and vomiting, may be treated with medications
7		that work as dopamine receptor blocking agents, including
8		antipsychotics and antiemetics; and
9		WHEREAS, While ongoing treatment with these medications
10		can be necessary, prolonged use is associated with tardive
11		dyskinesia (TD), an involuntary movement disorder that is
12		characterized by uncontrollable, abnormal, and repetitive
13		movements of the face, torso, limbs, and fingers or toes; and
14		WHEREAS, Even mild symptoms of TD can impact people
15		physically, socially, and emotionally; and
16		WHEREAS, It is estimated that TD affects approximately
17		600,000 people in the United States, and approximately 65
18		percent of people with TD have not been diagnosed, making it
19		important to raise awareness about the symptoms; and
20		WHEREAS, It is important that people taking these
21		medications be monitored for TD by a healthcare provider;

SR0735 - 2 - LRB103 35953 MST 66040 r
1		regular screening for TD is recommended by the American
2		Psychiatric Association; and
3		WHEREAS, Clinical research has led to approval of
4		treatments for adults with TD by the U.S. Food and Drug
5		Administration, and recognition and treatment of TD can make a
6		positive impact in the lives of many people experiencing
7		psychotic and mood disorders; and
8		WHEREAS, The Illinois Senate can utilize its position to
9		raise awareness of TD among the public and medical community;
10		therefore, be it
11		RESOLVED, BY THE SENATE OF THE ONE HUNDRED THIRD GENERAL
12		ASSEMBLY OF THE STATE OF ILLINOIS, that we declare May 5-11,
13		2024 as "Tardive Dyskinesia Awareness Week" in the State of
14		Illinois; and be it further